Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A discussion about hard belly and visceral fat
Understanding lipodystrophy among people living with HIV, including hard belly and visceral fat.
This special issue of POZ Focus is dedicated to understanding lipodystrophy among people living with HIV.
Lipo can be a constant reminder of living with HIV and can lead to loss of self-esteem and social withdrawal.
Those who exercise build up less liver fat, which is tied to inflammation that may give rise to cancer.
A recent study found that frailty was associated with bone and muscle loss and having a large waist.
A recent study found that the virus was associated with abdominal obesity as well as high triglycerides and low LDL cholesterol.
I know it won’t solve all my lipodystrophy challenges, but I’m feeling desperate to improve my body. Do you relate?
Taking Egrifta and getting CoolSculpt: Is this a midlife crisis or a healthy reality?
The drug Egrifta (tesamorelin), developed as a treatment for excess abdominal fat in people with HIV, may have an additional benefit of promot...
The injectable drug Egrifta (tesamorelin) led to modest drops in abdominal and liver fat levels in a preliminary study of people with HIV.
Slightly greater gains in trunk fat after switching to a new regimen containing Prezista, also reported increased satisfaction with bodies.
Egrifta (tesamorelin), a drug approved to reduce gut fat accumulation, also reduces cellular inflammation.
HIV-positive individuals experiencing a loss of muscle mass and an increase in abdominal fat may face an increased risk of death, according to...
Egrifta (tesamorelin) has been approved for the treatment of HIV-associated lipodystrophy, according to a November 10 announcement from...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.